SCIENTIFIC COMMITTEE CHAIRPERSONS:
Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA, USA (AACR)
James H. Doroshow, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA (NCI)
Ahmad A. Awada, Institut Jules Bordet, Brussels, Belgium (EORTC)
More than 3,000 researchers and scientists from leading industry, academic, and government institutions attended the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference at the Hynes Convention Center in Boston, MA, to discuss innovation in drug development, target selection, and the impact of new discoveries in molecular and cell biology.
The conference, hosted by AACR, NCI and EORTC, brought together leading academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection, and the impact of new discoveries in molecular and cell biology. Understanding the pathways and mechanisms which cause cancer and regulate the biological behavior of tumor cells has lead to the development of numerous new agents and innovative targets for clinical trials. The 2009 conference was organized to reflect the many recent advances in the early development of promising new compounds, which are in different levels of preclinical and clinical development. It brought together delegates from all over the world igniting a huge exchange of information and promoting and developing global partnerships in translational research.